CAR T-Cell Therapies & Bispecific Antibodies for Relapsed MCL

Here’s a ⁢breakdown of⁣ the​ key facts from the⁢ provided​ text, focusing on Mantle Cell ⁤Lymphoma (MCL)⁢ treatment:

Ancient ⁣Context & Traditional Treatment:

* ​ MCL was historically considered incurable, with treatment focused on symptom control and prolonging survival.
* ‌ Traditional first-line treatment for younger, fit patients involved intensive chemoimmunotherapy, followed by‌ autologous stem cell transplantation ‌(ASCT) and⁤ sometimes rituximab ​maintenance.

New Developments & Shifting Paradigms:

* ​ ⁤ BTK Inhibitors: The TRIANGLE study ‍showed that adding⁢ Bruton tyrosine kinase (BTK) inhibitors to initial treatment can achieve durable remissions without ASCT. Early use of BTK inhibitors also helps ⁣identify patients who are not responding well,⁢ allowing for quicker changes in ⁣treatment.⁣ BTK inhibitors are also now preferred for ⁢second-line treatment.
*⁣ Allogeneic HSCT: Remains the only possibly curative option, but is generally reserved for younger, fit patients.
* CAR T-cell‍ Therapy: ⁢Shows promise with high overall response rates (orrs) and durable remissions, even in heavily pretreated or⁢ BTK inhibitor-resistant patients. Brexucabtagene ‍autoleucel (Tecartus) achieved a 93%​ ORR and 67% complete response rate in trials.
* Challenges⁤ with CAR ⁢T-cell Therapy: Significant risk of severe ⁣toxicities (Cytokine Release Syndrome – CRS, and Immune Effector Cell-Associated Neurotoxicity Syndrome – ICANS), complex/costly⁤ manufacturing, and frequently enough requires bridging therapy.
* ⁢‌ BsAbs: ​(Bispecific⁤ antibodies) are ​mentioned as a ⁣potential future direction, but the text cuts off before detailing them.

Key Takeaway: Treatment for​ MCL is evolving rapidly. ‍ BTK inhibitors and CAR T-cell therapies are offering new hope and potentially curative options, but⁣ also come with their own challenges.